Quality of life improvement is maintained up to two years after transcatheter aortic valve implantation in high-risk surgical candidates

Maurizio Taramasso, Azeem Latib, Micaela Cioni, Paolo Denti, Nicola Buzzatti, Cosmo Godino, Alaide Chieffo, Ottavio Alfieri, Antonio Colombo, Francesco Maisano

Research output: Contribution to journalArticle

Abstract

Aims: The aim of the study was to investigate the changes in quality of life (QoL) following transcatheter aortic valve implantation (TAVI) up to two years' follow-up. Methods and results: One hundred consecutive patients (46 females, mean age 79.7±6.1 years) with at least two years' follow-up who underwent TAVI in our institution, between November 2007 and September 2009, were enrolled in this study. Peak and mean aortic gradients were 87.8±25.8 mmHg and 53.3±15.4 mmHg, respectively. Mean log EuroSCORE was 27.9±15.9. Patients had multiple comorbidities. All patients underwent a standardised prospective screening pathway, including QoL evaluation with the 36-item short-form health survey (SF-36v2®) and the Minnesota Living with Heart Failure Questionnaires (MLHFQ). The scores obtained preoperatively were compared with those obtained at two years' follow-up. An Edwards SAPIEN valve (Edwards Lifesciences, Irvine, CA, USA) was implanted in 67 patients (55 transfemoral and 12 transapical) and a CoreValve (Medtronic, Inc., Minneapolis, MN, USA) was implanted in 33 patients (26 transfemoral and seven transaxillary). Thirty-day mortality was 4%. Actuarial survival was 80.6±4.1%, 72.6±4.7% and 63.2±6.3% at one, two and three years, respectively. Mean SF36-physical improved from 31.9±8.8 to 51.5±9.5 (p

Original languageEnglish
Pages (from-to)429-436
Number of pages8
JournalEuroIntervention
Volume8
Issue number4
DOIs
Publication statusPublished - Aug 2012

Fingerprint

Quality Improvement
Quality of Life
Health Surveys
Comorbidity
Heart Failure
Transcatheter Aortic Valve Replacement
Survival
Mortality

Keywords

  • Aortic stenosis
  • Quality of life
  • TAVI

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Quality of life improvement is maintained up to two years after transcatheter aortic valve implantation in high-risk surgical candidates. / Taramasso, Maurizio; Latib, Azeem; Cioni, Micaela; Denti, Paolo; Buzzatti, Nicola; Godino, Cosmo; Chieffo, Alaide; Alfieri, Ottavio; Colombo, Antonio; Maisano, Francesco.

In: EuroIntervention, Vol. 8, No. 4, 08.2012, p. 429-436.

Research output: Contribution to journalArticle

Taramasso, Maurizio ; Latib, Azeem ; Cioni, Micaela ; Denti, Paolo ; Buzzatti, Nicola ; Godino, Cosmo ; Chieffo, Alaide ; Alfieri, Ottavio ; Colombo, Antonio ; Maisano, Francesco. / Quality of life improvement is maintained up to two years after transcatheter aortic valve implantation in high-risk surgical candidates. In: EuroIntervention. 2012 ; Vol. 8, No. 4. pp. 429-436.
@article{3d7370aae2304b6c8b4bdd29675d7ece,
title = "Quality of life improvement is maintained up to two years after transcatheter aortic valve implantation in high-risk surgical candidates",
abstract = "Aims: The aim of the study was to investigate the changes in quality of life (QoL) following transcatheter aortic valve implantation (TAVI) up to two years' follow-up. Methods and results: One hundred consecutive patients (46 females, mean age 79.7±6.1 years) with at least two years' follow-up who underwent TAVI in our institution, between November 2007 and September 2009, were enrolled in this study. Peak and mean aortic gradients were 87.8±25.8 mmHg and 53.3±15.4 mmHg, respectively. Mean log EuroSCORE was 27.9±15.9. Patients had multiple comorbidities. All patients underwent a standardised prospective screening pathway, including QoL evaluation with the 36-item short-form health survey (SF-36v2{\circledR}) and the Minnesota Living with Heart Failure Questionnaires (MLHFQ). The scores obtained preoperatively were compared with those obtained at two years' follow-up. An Edwards SAPIEN valve (Edwards Lifesciences, Irvine, CA, USA) was implanted in 67 patients (55 transfemoral and 12 transapical) and a CoreValve (Medtronic, Inc., Minneapolis, MN, USA) was implanted in 33 patients (26 transfemoral and seven transaxillary). Thirty-day mortality was 4{\%}. Actuarial survival was 80.6±4.1{\%}, 72.6±4.7{\%} and 63.2±6.3{\%} at one, two and three years, respectively. Mean SF36-physical improved from 31.9±8.8 to 51.5±9.5 (p",
keywords = "Aortic stenosis, Quality of life, TAVI",
author = "Maurizio Taramasso and Azeem Latib and Micaela Cioni and Paolo Denti and Nicola Buzzatti and Cosmo Godino and Alaide Chieffo and Ottavio Alfieri and Antonio Colombo and Francesco Maisano",
year = "2012",
month = "8",
doi = "10.4244/EIJV8I4A68",
language = "English",
volume = "8",
pages = "429--436",
journal = "EuroIntervention",
issn = "1774-024X",
publisher = "EuroPCR",
number = "4",

}

TY - JOUR

T1 - Quality of life improvement is maintained up to two years after transcatheter aortic valve implantation in high-risk surgical candidates

AU - Taramasso, Maurizio

AU - Latib, Azeem

AU - Cioni, Micaela

AU - Denti, Paolo

AU - Buzzatti, Nicola

AU - Godino, Cosmo

AU - Chieffo, Alaide

AU - Alfieri, Ottavio

AU - Colombo, Antonio

AU - Maisano, Francesco

PY - 2012/8

Y1 - 2012/8

N2 - Aims: The aim of the study was to investigate the changes in quality of life (QoL) following transcatheter aortic valve implantation (TAVI) up to two years' follow-up. Methods and results: One hundred consecutive patients (46 females, mean age 79.7±6.1 years) with at least two years' follow-up who underwent TAVI in our institution, between November 2007 and September 2009, were enrolled in this study. Peak and mean aortic gradients were 87.8±25.8 mmHg and 53.3±15.4 mmHg, respectively. Mean log EuroSCORE was 27.9±15.9. Patients had multiple comorbidities. All patients underwent a standardised prospective screening pathway, including QoL evaluation with the 36-item short-form health survey (SF-36v2®) and the Minnesota Living with Heart Failure Questionnaires (MLHFQ). The scores obtained preoperatively were compared with those obtained at two years' follow-up. An Edwards SAPIEN valve (Edwards Lifesciences, Irvine, CA, USA) was implanted in 67 patients (55 transfemoral and 12 transapical) and a CoreValve (Medtronic, Inc., Minneapolis, MN, USA) was implanted in 33 patients (26 transfemoral and seven transaxillary). Thirty-day mortality was 4%. Actuarial survival was 80.6±4.1%, 72.6±4.7% and 63.2±6.3% at one, two and three years, respectively. Mean SF36-physical improved from 31.9±8.8 to 51.5±9.5 (p

AB - Aims: The aim of the study was to investigate the changes in quality of life (QoL) following transcatheter aortic valve implantation (TAVI) up to two years' follow-up. Methods and results: One hundred consecutive patients (46 females, mean age 79.7±6.1 years) with at least two years' follow-up who underwent TAVI in our institution, between November 2007 and September 2009, were enrolled in this study. Peak and mean aortic gradients were 87.8±25.8 mmHg and 53.3±15.4 mmHg, respectively. Mean log EuroSCORE was 27.9±15.9. Patients had multiple comorbidities. All patients underwent a standardised prospective screening pathway, including QoL evaluation with the 36-item short-form health survey (SF-36v2®) and the Minnesota Living with Heart Failure Questionnaires (MLHFQ). The scores obtained preoperatively were compared with those obtained at two years' follow-up. An Edwards SAPIEN valve (Edwards Lifesciences, Irvine, CA, USA) was implanted in 67 patients (55 transfemoral and 12 transapical) and a CoreValve (Medtronic, Inc., Minneapolis, MN, USA) was implanted in 33 patients (26 transfemoral and seven transaxillary). Thirty-day mortality was 4%. Actuarial survival was 80.6±4.1%, 72.6±4.7% and 63.2±6.3% at one, two and three years, respectively. Mean SF36-physical improved from 31.9±8.8 to 51.5±9.5 (p

KW - Aortic stenosis

KW - Quality of life

KW - TAVI

UR - http://www.scopus.com/inward/record.url?scp=84872068334&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872068334&partnerID=8YFLogxK

U2 - 10.4244/EIJV8I4A68

DO - 10.4244/EIJV8I4A68

M3 - Article

C2 - 22917725

AN - SCOPUS:84872068334

VL - 8

SP - 429

EP - 436

JO - EuroIntervention

JF - EuroIntervention

SN - 1774-024X

IS - 4

ER -